HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Net Income

Bottom-line profit, the starting point for calculating cash from operations.

HUTCHMED (China) LimitedNASDAQ: HCM

Net Income · Q2 FY2025 · quarter ended Jun 2025

Net income growth accelerates

Q2 FY2025 net income of $227.48M rose 1663.3% year over year, ahead of the +1212.4% change in trailing-twelve-month net income. Sequentially, it rose 0.0% from the prior quarter.

Context

  • Net income amounted to 83.3% of revenue in FY2025, up 77.3 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 16 analysts of $68.19M (-85.1%) for the fiscal year ending Dec 2026, a slowdown from the +1114.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2025
$227.48M+0.0% QoQ
Last fiscal yearDec 2025
$458.12M+1114.2% YoY
LTMJun 2025
$466.88M+1212.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1663.3%-1027.8%-2691.1 pp
1 year+1114.2%-85.1%-1199.3 pp
3-year CAGR—-39.8%—
5-year CAGR-14.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
458.12M USD
Year-over-year change
+1114.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1212.4% is the highest of 9, against a peer median of +48.6%.
  • Net income amounts to 77.5% of revenue for HCM, versus a peer median of 52.0%.
HCM Competitors
Net Income for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.71B EUR+348.2%—64.7%
INCYIncyte CorporationLTM Jun 2026$1.61B USD+85.1%+55.7%27.7%
AAPGAscentage Pharma Group InternationalFY2025CN¥1.24B CNY+212.7%+11.7%221.3%
GMABGenmab A/SLTM Jun 2026$861.1M USD—-48.4%20.8%
EXELExelixis, Inc.LTM Jul 2026$860.62M USD+42.9%+62.5%35.3%
HCMHUTCHMED (China) LimitedLTM Jun 2025$466.88M USD+1212.4%—77.5%
RCUSArcus Biosciences, Inc.LTM Jun 2026$460M USD+54.4%+9.8%393.2%
ZLABZai Lab LimitedLTM Jun 2026$188.21M USD-11.4%-26.6%41.9%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$140.06M USD-54.4%+24.7%62.2%
ANLAdlai Nortye Ltd.LTM Jun 2024$54.07M USD—-15.4%833.1%
LEGNLegend Biotech CorporationLTM Sep 2026$2.81M USD-98.7%-12.6%0.2%
Peer median (excluding HCM) —+48.6%+9.8%52.0%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.04M)(360.39M)100.78M37.73M458.12M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
Deferred Income Tax(115.14M)0(102.76M)00
Stock-Based Compensation41.99M30.59M36.6M21.61M15.29M
Change in Working Capital32.46M58.7M71.15M(62.17M)(61.02M)
Accounts Receivables(35.63M)(14.45M)(21.34M)(41.57M)28.94M
Inventory(16M)(21.21M)4.14M(772K)9.57M
Accounts Payables9.57M29.94M(32.54M)03.02M
Other Working Capital74.53M64.04M120.89M(19.82M)(102.55M)
Other Non-Cash Items(3.68M)(6.17M)105.28M(9.01M)(490.56M)
Operating Cash Flow(204.22M)(268.6M)219.26M497K(64.83M)
Capital Expenditures(16.76M)(36.66M)(32.61M)(17.93M)(14.19M)
Acquisitions (Net)159.12M324K(2.99M)028.07K
Purchases of Investments(1.37B)(1.2B)(1.63B)(1.85B)(2.75B)
Sales of Investments921.36M1.52B1.37B1.77B2.74B
Other Investing Activities930K16.49M29.5M1.28M0
Investing Cash Flow(306.32M)296.59M(291.14M)(96.06M)(29.49M)
Debt Repayment(579.77K)(9.17M)61.71M5.61M6.27M
Common Stock Issued717.32M174K5.09M790K1.58M
Common Stock Repurchased(27.31M)(48.08M)(9.07M)(36.06M)0
Dividends Paid(99.74M)(87.44M)000
Other Financing Activities60.34M61.75M(9.07M)(1M)0
Financing Cash Flow650.03M(82.76M)48.66M(30.67M)7.86M
Effect of Forex Changes2.43M(9.49M)(6.47M)(3.4M)3.83M
Net Change in Cash141.91M(64.26M)(29.69M)(129.63M)(82.63M)
Free Cash Flow(220.98M)(305.26M)186.65M(17.44M)(79.01M)

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.